Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 8 studies | 23% ± 4% | |
glutamatergic neuron | 5 studies | 44% ± 22% | |
epithelial cell | 5 studies | 30% ± 7% | |
neuron | 4 studies | 24% ± 6% | |
fibroblast | 4 studies | 19% ± 2% | |
GABAergic neuron | 4 studies | 40% ± 15% | |
astrocyte | 4 studies | 24% ± 5% | |
oligodendrocyte | 4 studies | 22% ± 2% | |
natural killer cell | 3 studies | 21% ± 4% | |
B cell | 3 studies | 19% ± 2% | |
pericyte | 3 studies | 22% ± 2% | |
rod bipolar cell | 3 studies | 18% ± 2% | |
oligodendrocyte precursor cell | 3 studies | 27% ± 6% | |
goblet cell | 3 studies | 25% ± 12% | |
interneuron | 3 studies | 39% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3475.96 | 1445 / 1445 | 100% | 12.01 | 183 / 183 |
lung | 100% | 3237.31 | 578 / 578 | 100% | 10.68 | 1155 / 1155 |
brain | 100% | 3480.65 | 2640 / 2642 | 100% | 14.03 | 705 / 705 |
breast | 100% | 3552.16 | 459 / 459 | 100% | 14.92 | 1117 / 1118 |
kidney | 100% | 2671.97 | 89 / 89 | 100% | 15.08 | 900 / 901 |
prostate | 100% | 3022.45 | 245 / 245 | 100% | 11.76 | 501 / 502 |
adrenal gland | 100% | 3102.47 | 258 / 258 | 100% | 11.82 | 229 / 230 |
ovary | 100% | 3687.02 | 180 / 180 | 100% | 7.06 | 428 / 430 |
thymus | 100% | 3716.20 | 653 / 653 | 100% | 13.02 | 602 / 605 |
bladder | 100% | 3073.67 | 21 / 21 | 99% | 9.17 | 501 / 504 |
stomach | 100% | 2708.42 | 359 / 359 | 99% | 8.83 | 284 / 286 |
uterus | 100% | 3622.89 | 170 / 170 | 99% | 10.13 | 455 / 459 |
pancreas | 100% | 2205.16 | 328 / 328 | 99% | 10.79 | 176 / 178 |
intestine | 100% | 3240.35 | 966 / 966 | 98% | 8.81 | 519 / 527 |
liver | 100% | 2065.72 | 226 / 226 | 98% | 7.88 | 399 / 406 |
skin | 100% | 3689.73 | 1809 / 1809 | 93% | 8.53 | 441 / 472 |
adipose | 100% | 3411.76 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3326.02 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 3105.92 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 10.18 | 45 / 45 |
muscle | 100% | 3378.02 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2572.33 | 856 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 5.34 | 27 / 29 |
peripheral blood | 78% | 1093.24 | 725 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 74% | 4.12 | 59 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0006508 | Biological process | proteolysis |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXO3 |
Protein name | F-box protein 3 F-box protein 3 (FBXO3 protein) (cDNA, FLJ79185, highly similar to F-box only protein 3) F-box only protein 3 F-box protein 3 (cDNA FLJ59154, highly similar to F-box only protein 3) |
Synonyms | hCG_27567 FBX3 |
Description | FUNCTION: Substrate recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex, SCF(FBXO3), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins . Mediates the ubiquitination of HIPK2 and probably that of EP300, leading to rapid degradation by the proteasome . In the presence of PML, HIPK2 ubiquitination still occurs, but degradation is prevented . PML, HIPK2 and FBXO3 may act synergically to activate p53/TP53-dependent transactivation . The SCF(FBXO3) also acts as a regulator of inflammation by mediating ubiquitination and degradation of FBXL2 in response to lipopolysaccharide (LPS) . The SCF(FBXO3) complex specifically recognizes FBXL2 phosphorylated at 'Thr-404' and promotes its ubiquitination (By similarity). . |
Accessions | ENST00000448981.6 [Q9UK99-2] ENST00000526785.5 ENST00000532927.5 ENST00000530401.5 [Q9UK99-3] G3V1E0 ENST00000265651.8 [Q9UK99-1] ENST00000534136.5 E9PL46 ENST00000529137.1 ENST00000532057.5 E9PJM3 Q49AF1 B4E3U2 Q9UK99 ENST00000531080.5 |